Bod secures first prescription for MediCabilis cannabis oil and new research partner

Bod secures first prescription for MediCabilis cannabis oil and new research partner

It has been a long time coming for listed medicinal cannabis player Bod Australia (ASX: BDA), but they've finally secured their first prescription.

The company announced this morning that it has received its first prescription and required Special Access Scheme approvals for its MediCabilis cannabis oil product.

The approval should give Bod a boost in sales of cannabis oil in the near term.

Additionally, the company has announced its new research collaboration with Biologics Research Institute Australia (BRIA) the owners and operators of Cannabis Access Clinics.

Research will be conducted into the effects of the MediCabilis product on a broad range of patient outcomes.

The agreement is important for the company because once the research is completed MediCabilis will be made available to patients in Cannabis Access' network to prescribe when appropriate.

Cannabis Access Clinics have an extensive network of healthcare clinics assisting doctors and patients to navigate the (at times confusing) regulatory approvals for prescribing medicinal cannabis products in Australia and New Zealand.

The trial will provide feedback on MediCabilis' ability to treat a range of symptoms including anxiety, pain, post chemotherapy nausea & vomiting, and epilepsy.

Bod CEO Jo Patterson says today's news is important for the ongoing growth of the company and its ability to reach more patients in need of the product.

"This agreement is very beneficial for Bod, as it has not only resulted in the company receiving its first prescription for MediCabilis, but also provides us with a large pool of potential patients and prescribers from the Cannabis Access Clinics network that will provide ongoing feedback around our medicinal cannabis product offering," says Patterson.

Shares in Bod are down 1.74 per cent to $0.56 per share at 11.04am AEST.

READ MORE: The Cannabis Index: A complete guide to cannabis stocks on the ASX

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Subscribe Now!
Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

HMC Capital enters private credit market with $127.5m purchase of Payton Capital

HMC Capital enters private credit market with $127.5m purchase of Payton Capital

After more than a year of due diligence and amidst plans to lift it...

Cost of living elevates salaries and perks as key drivers of employee retention in 2024

Cost of living elevates salaries and perks as key drivers of employee retention in 2024

The cost of living is making salaries and perks just as important a...

Enterprise roll-out "one of the biggest launches in Canva's history" as ARR hits $2.2b

Enterprise roll-out "one of the biggest launches in Canva's history" as ARR hits $2.2b

Sydney-headquartered graphic design and visualisation tool giant Ca...

The Star unsuitable to hold a casino licence, final Bell Inquiry submissions claim

The Star unsuitable to hold a casino licence, final Bell Inquiry submissions claim

The Star Entertainment Group (ASX: SGR) has been declared unsuitabl...